multiple myeloma tagged posts

1. Professor Kim De Keersmaecker (KU Leuven, Belgium) is shown.
Credit: KU Leuven – Rob Stevens. 2. In patients with multiple myeloma, the plasma cells in the bone marrow start proliferating malignantly.

20 – 40% of the patients with multiple myeloma have a defect in the ribosome, protein factory of the cell. These patients have a poorer prognosis than patients with intact ribosomes. At the same time, they respond better to a drug that already exists. These are the findings of a study by the Laboratory for Disease Mechanisms in Cancer at KU Leuven, Belgium.

Multiple myeloma (MM, also known as Kahler’s disease) is a blood cancer whereby the plasma cells in the bone marrow start proliferating malignantly. MM cannot be cured and is most common among older people...

Image: Based upon conserved snoRNA sequence elements, this large population of guide RNAs has been divided into two major families designated the box C/D and the box H/ACA snoRNAs. The primary function of the box C/D snoRNAs is to guide 2′-O-methylation of targeted rRNA nucleotides while the box H/ACA snoRNAs direct the conversion of specific uridine residues to pseudouridine.

Scientists have discovered unexpected functions of small nucleolar RNAs (snoRNAs) that explain the cause of some genetic diseases and cancers. However, it is not clear how the change in snoRNA expression could lead to these diseases. Using RNA sequencing and molecular biology techniques, researchers found snoRNAs not only modify ribosomes, but can also regulate alternative splicing...